• Publications
  • Influence
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
TLDR
This trial is the largest in recurrent ovarian cancer and has demonstrated superiority in PFS and better therapeutic index of CD over standard CP and better quality of life, and overall survival. Expand
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
TLDR
EGFR mutation is a predictive biomarker of PFS benefit with EGFR-TKIs treatment in all settings and should be considered as front-line therapy in EGFRmut(+) advanced NSCLC patients, supporting EGFR mutation assessment before initiation of treatment. Expand
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
TLDR
CP and CD were equally effective treatment regimens for patients with very platinum-sensitive recurrent ovarian cancer, and the favourable risk-benefit profile suggests carboplatin-PLD as treatment of choice for these patients. Expand
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.
TLDR
The role of early decline in cancer antigen 125 (CA125) and early tumor response as prognostic factors and surrogates for superiority of treatment with carboplatin-pegylated liposomal doxorubicin (CPLD) compared with carbplatin-paclitaxel (CP) is examined in a landmark analysis. Expand
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
TLDR
The combination of durvalumab, cisplatin, and pemetrexed has promising activity and an acceptable safety profile that warrants further investigation in a randomised phase 3 trial. Expand
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
TLDR
This phase II, single arm trial investigated the efficacy and safety of BNC105P as second line therapy in MPM and found the sole response was insufficient to warrant further research as a single agent. Expand
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
TLDR
Combination treatment compared with single-agent irinotecan reduces alopecia and diarrhoea without compromising efficacy on clinical outcomes, and both regimens remain as reasonable treatment options. Expand
Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: what makes it worthwhile?
TLDR
Most lung cancer clinicians attending a national lung cancer conference judged moderate improvements in survival sufficient to make adjuvant chemotherapy worthwhile, and Clinicians should be aware of their own preferences, and explore their patients' preferences, when discussing adjUvant chemotherapy. Expand
Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas
TLDR
This treatment combination had moderate activity with acceptable toxicity, supporting previous results that this combination has a role to play, and does not suggest that FDR gemcitabine is superior to bolus infusion. Expand
...
1
2
...